Relevant bibliographies by topics / Pharmaco-economic analysis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Pharmaco-economic analysis'

Author: Grafiati
Published: 4 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaco-economic analysis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaco-economic analysis"

1

Kamusheva, Maria, Yanitsa Rusenova, Silvia Vandeva, et al. "Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review." Biotechnology & Biotechnological Equipment 33, no. 1 (2019): 1560–71. http://dx.doi.org/10.1080/13102818.2019.1680317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Кадысева, Э. Р., and В. Н. Хазиахметова. "PHARMACO-ECONOMIC ANALYSIS OF ANTICOAGULANTS USED IN THE BURN DEPARTMENT." Фармакология & Фармакотерапия, no. 1 (May 29, 2024): 14–16. http://dx.doi.org/10.46393/27132129_2024_1_14.

Full text
Abstract:
Проблема профилактики и лечения тромбозов продолжает оставаться актуальной для современной медицины. Ранняя диагностика тромботической готовности имеет важное практическое значение для первичной и вторичной профилактики. Особую группу пациентов хирургического профиля составляют больные с ожоговой травмой. Данные пациенты, с повреждением кожи и подлежащих тканей, относятся к группе умеренного и высокого риска венозных тромбоэмболических осложнений ввиду изменений состояния системы гемостаза, которые могут проявляться в виде тромботических или геморрагических осложнений. В статье представлен сравнительный анализ эффективности, безопасности и стоимости применения различных антикоагулянтов у пациентов ожогового профиля. The problem of prevention and treatment of thrombosis continues to be relevant for modern medicine. Early diagnosis of thrombotic readiness is of great practical importance for primary and secondary prevention. A special group of surgical patients consists of patients with burn injuries. These patients, with damage to the skin and underlying tissues, belong to the group of moderate and high risk of venous thromboembolic complications due to changes in the state of the hemostatic system, which can manifest themselves in the form of thrombotic or hemorrhagic complications. The article presents a comparative analysis of the efficacy, safety and cost of using various anticoagulants in burn patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Valpiani, G., Esposti L. Degli, S. Saragoni, and Esposti E. Degli. "PCV29: PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY: A PHARMACO-UTILIZATION AND PHARMACO-ECONOMIC ANALYSIS." Value in Health 4, no. 6 (2001): 499. http://dx.doi.org/10.1016/s1098-3015(11)71731-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zure, Diaiti, Meng-Hau Sung, Abdul Rahim, and Hsion-Wen Kuo. "In Silico Assessment of Chemical Disinfectants on Surface Proteins Unveiled Dissimilarity in Antiviral Efficacy and Suitability towards Pathogenic Viruses." International Journal of Molecular Sciences 25, no. 11 (2024): 6009. http://dx.doi.org/10.3390/ijms25116009.

Full text
Abstract:
Viral pathogens pose a substantial threat to public health and necessitate the development of effective remediation and antiviral strategies. This short communication aimed to investigate the antiviral efficacy of disinfectants on the surface proteins of human pathogenic viruses. Using in silico modeling, the ligand-binding energies (LBEs) of selected disinfectants were predicted and combined with their environmental impacts and costs through an eco-pharmaco-economic analysis (EPEA). The results revealed that the binding affinities of chemical disinfectants to viral proteins varied significantly (p < 0.005). Rutin demonstrated promising broad-spectrum antiviral efficacy with an LBE of −8.49 ± 0.92 kcal/mol across all tested proteins. Additionally, rutin showed a superior eco-pharmaco-economic profile compared to the other chemicals, effectively balancing high antiviral effectiveness, moderate environmental impact, and affordability. These findings highlight rutin as a key phytochemical for use in remediating viral contaminants.
APA, Harvard, Vancouver, ISO, and other styles
5

Iwai, Mina, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura, and Hitomi Teramachi. "Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer." Molecular and Clinical Oncology 6, no. 5 (2017): 794–98. http://dx.doi.org/10.3892/mco.2017.1218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sørensen, Henrik Toft, Flemming Hald Steffensen, Gunnar Lauge Nielsen, and Poul Grøn. "Variation in antibiotic prescribing costs in Danish general practice: an epidemiological pharmaco-economic analysis." International Journal of Risk and Safety in Medicine 8, no. 3 (1996): 243–50. http://dx.doi.org/10.3233/jrs-1996-8308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brīdiņa, Linda, Angelika Krūmiņa, Oļegs Šuba, Vinita Cauce, Indulis Vanags, and Ludmila Vīksna. "Severe Sepsis – Clinical Manifestations and Pharmaco-Economic Analysis in an Intensive Care Unit in Latvia." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 70, no. 4 (2016): 237–44. http://dx.doi.org/10.1515/prolas-2016-0024.

Full text
Abstract:
Abstract Sepsis is widespread among hospitalised patients worldwide. In fact, severe sepsis and septic shock is a major cause of patient admission and mortality in intensive care units and the difficulty in diagnosing the initial stage of the disease is a major obstacle to the reduction of mortality from sepsis. Retrospective analysis of medical records of 72 patients was carried out within the framework of the study. The study included patients of both sexes and all ages, who were hospitalised at the stationary “Gaiļezers” of the Rīga East Clinical University Hospital from 2011 to 2014. The study aim was to determine the clinical course of treated septic patients and conduct a pharmaco-economic analysis. In the course of the disease, almost half of the patients - 34 (48.6%) showed development of septic shock. Mortality in these patients exceeded a half (60.0%; 21 patients). Artificial lung ventilation during hospitalisation was received by 43 (59.7%) of patients. Artificial lung ventilation had been required in a significantly larger number of cases in the dead patient group (75%, p = 0.01). The average costs per one patient day (including bed-day price and manipulation costs) was 383 euros. Septic shock was associated with high mortality. Severe sepsis is an expensive diagnosis, as the average cost of one patient exceeds costs of other departments by 4.5 times.
APA, Harvard, Vancouver, ISO, and other styles
8

Krasavtsev, E. L., V. M. Mitsura та A. P. Demchilo. "EFFICIENCY OF VARIOUS SCHEMES OF INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS С". Health and Ecology Issues, № 1 (28 березня 2011): 90–95. http://dx.doi.org/10.51523/2708-6011.2011-8-1-17.

Full text
Abstract:
Comparison of different schemes of interferon therapy efficiency is studied in patients with chronic hepatitis C with various viral genotypes. On treatment of chronic hepatitis C it is necessary to be guided not only on clinical, but also pharmaco-economic efficiency of therapy. By means of «cost-effectiveness» analysis it is established that the best price/quality ratio has the scheme with use of interferon monotherapy with high-doses beginning.
APA, Harvard, Vancouver, ISO, and other styles
9

McNamara, J., and S. Gillis. "SR2: A PHARMACO-ECONOMIC CASE STUDY IN ANAESTHESIA, INCLUDING A RECENT RE-ANALYSIS USING BOOTSTRAP TECHNIQUES." Value in Health 2, no. 5 (1999): 364. http://dx.doi.org/10.1016/s1098-3015(10)75794-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Elsamany, Shereef Ahmed, Mohamed Jafal, and Fayza Hassanin. "Pharmaco-economic assessment of subcutaneous compared to intravenous trastuzumab in HER2-positive breast cancer patients: A single institution experience." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19409-e19409. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19409.

Full text
Abstract:
e19409 Background: Traditionally, trastuzumab is given through intravenous (IV) administration. Recently, subcutaneous (SC) trastuzumab formulation has been developed showing similar efficacy and safety with shorter administration time. This study aims to assess the pharmaco-economics of SC compared to IV trastuzumab in patients with HER2-positive breast cancer treated in a single institution in Saudi Arabia. Methods: We checked the average number of trastuzumab doses, both IV and SC, given per year in King Abdullah Medical City, Saudi Arabia. One-year pharmaco-economic analysis of either trastuzumab forms were performed separately. This analysis included direct medication price based on hospital purchasing in addition to costs of drug preparation kits, nursing administration utilities and staff working time, based on average duration of drug preparation/ administration in chemotherapy unit records. IV trastuzumab dose was calculated based on an average body weight of 80 kg. Results: On average, the total number of trastuzumab doses, both IV and SC, were 1000 doses per year. We calculated the overall cost of 1000 doses of IV compared to SC trastuzumab separately. The average costs of one dose of IV and SC trastuzumab were 2,099 and 1,619 USD, respectively. This is translated to 2,099,000 and 1,619,000 USD per year for IV and SC trastuzumab, respectively. Other costs of trastuzumab administration were 24,933 and 2,666 USD per year of IV and SC trastuzumab, respectively. IV and SC trastuzumab administration needed 2,000 and 83 working hours per year, respectively, resulting in 1,917 saving in nursing working hours per year. This is translated to 18,106 USD saving per year based on average nursing salary. IV and SC trastuzumab pharmacy preparation needed 333 and 33 working hours per year, respectively, corresponding to annual saving of 300 hours in pharmacist- working time and 10,106 USD of pharmacist salary. The overall cost of IV trastuzumab per year was 2,153,667 compared to 1,623,236 USD for SC trastuzumab which corresponds to 2,153 and 1,623 USD per dose for IV and SC trastuzumab, respectively. This is translated to 24.6% overall cost reduction with the SC formulation. Conclusions: SC trastuzumab is associated with favorable pharmaco-economic profile with considerable cost saving compared to the IV counterpart. This is coupled with significant reduction of administration time and improved convenience.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaco-economic analysis"

1

Wadt, Marcelo. "Análise econômica de novos fármacos licenciados no Brasil entre 1998 e 2001." Universidade de São Paulo, 2003. http://www.teses.usp.br/teses/disponiveis/9/9139/tde-07112006-100751/.

Full text
Abstract:
O levantamento do número de medicamentos inovadores licenciados no Brasil pela agência reguladora de medicamentos durante quatro anos, entre 1998 e 2001, mostrou 154 medicamentos inovadores (fármacos com nova estrutura molecular). A maioria deles (57,1% do total) foi concentrada em quatro classes terapêuticas: quimioterapia sistêmica (39 produtos), analgesia e anestesia (20), aparelho cardiovascular (15) e hormônios e anti-hormônios (14). Medicamentos inovadores para uso crônico foram lançados com preços mais altos com relação às opções pré-existentes de sua mesma classe terapêutica. Quando comparados apenas a fármacos com estrutura química semelhante, o custo foi menor. O custo estimado de tratamento por um mês variou entre 14% do salário mínimo (R$ 27,90) até 580% (R$ 1.159,80), portanto quase seis vezes. O estudo mostrou que no Brasil os medicamentos inovadores não são acessíveis para as famílias de baixa renda.<br>During the four-year period of 1998-2001, the Brazilian government licensed 154 medicines with new molecular entities. Most of them (57,1%) belong to only four therapeutic classes: anti-infectives (39 products), anesthetics and analgesics (20), cardiovascular (15) and hormones and anti-hormones (14). New medicines for chronic term use were launched with prices higher than the pre-existing competitors of the same therapeutic class. When compared with drugs resembling similar molecular structure, the price was lower. When compared to the minimal monthly wage, the estimated cost of on month of treatment was between 14% (R$ 27,90) and 580% (1159,80), therefore almost six times more. The study showed that in Brasil medicines with new molecular entities are not affordable to families with low income.
APA, Harvard, Vancouver, ISO, and other styles
2

Guertin, Jason R. "Recherche économique en santé cardiovasculaire." Thèse, 2010. http://hdl.handle.net/1866/4052.

Full text
Abstract:
Les nouvelles technologies médicales contribuent aux dépenses en santé qui ne cessent de croître, alors que les budgets se trouvent limités. L’évaluation économique des technologies devraient permettre d’identifier quelles sont celles qui sont les plus rentables. Malgré cela, plusieurs technologies dont le rapport coût-efficacité reste plutôt limite ou défavorable sont utilisées en médecine moderne et remboursées par notre système public de santé. Ce mémoire se concentre sur deux technologies en santé cardiovasculaire dont le rapport coût-efficacité est plutôt limite mais qui sont fréquemment utilisées au Canada; les tuteurs médicamentés ou pharmaco-actifs et les défibrillateurs cardiaques implantables (DCI). Nous avons fait une évaluation contingente de ces technologies dans le but d’examiner si ce type d’évaluation économique complémentaire pouvait procurer un point de vue nouveau sur la valeur économique et sociétaire des ces technologies. Les résultats de ces deux évaluations indiquent que les patients accordent une grande importance aux bénéfices que procurent ces deux technologies. Nos résultats soutiennent les politiques de santé actuelles de rembourser de façon libérale ces deux technologies.<br>Technological innovations have greatly contributed to the rising costs in healthcare, while budgets have remained limited. Economic evaluations of technologies should identify which technologies are cost-effective. However, several technologies used in modern medicine are either borderline cost-effective or even not cost-effective according to many studies. This thesis focuses on two technologies in cardiovascular medicine which are considered borderline cost-effective; drug-eluting stents and implantable cardioverter defibrillators. We conducted a contingent valuation of these technologies in hopes of determining if this alternative type of economic evaluation could give a novel point of view on the economic and societal value of these technologies. Results indicated that patients greatly valued benefits provided by these two technologies. Our result support our public healthcare system policies’ of liberal reimbursement of these two technologies.
APA, Harvard, Vancouver, ISO, and other styles
3

Guertin, Jason Robert. "Recherche économique en santé cardiovasculaire." Thèse, 2010. http://hdl.handle.net/1866/4052.

Full text
Abstract:
Les nouvelles technologies médicales contribuent aux dépenses en santé qui ne cessent de croître, alors que les budgets se trouvent limités. L’évaluation économique des technologies devraient permettre d’identifier quelles sont celles qui sont les plus rentables. Malgré cela, plusieurs technologies dont le rapport coût-efficacité reste plutôt limite ou défavorable sont utilisées en médecine moderne et remboursées par notre système public de santé. Ce mémoire se concentre sur deux technologies en santé cardiovasculaire dont le rapport coût-efficacité est plutôt limite mais qui sont fréquemment utilisées au Canada; les tuteurs médicamentés ou pharmaco-actifs et les défibrillateurs cardiaques implantables (DCI). Nous avons fait une évaluation contingente de ces technologies dans le but d’examiner si ce type d’évaluation économique complémentaire pouvait procurer un point de vue nouveau sur la valeur économique et sociétaire des ces technologies. Les résultats de ces deux évaluations indiquent que les patients accordent une grande importance aux bénéfices que procurent ces deux technologies. Nos résultats soutiennent les politiques de santé actuelles de rembourser de façon libérale ces deux technologies.<br>Technological innovations have greatly contributed to the rising costs in healthcare, while budgets have remained limited. Economic evaluations of technologies should identify which technologies are cost-effective. However, several technologies used in modern medicine are either borderline cost-effective or even not cost-effective according to many studies. This thesis focuses on two technologies in cardiovascular medicine which are considered borderline cost-effective; drug-eluting stents and implantable cardioverter defibrillators. We conducted a contingent valuation of these technologies in hopes of determining if this alternative type of economic evaluation could give a novel point of view on the economic and societal value of these technologies. Results indicated that patients greatly valued benefits provided by these two technologies. Our result support our public healthcare system policies’ of liberal reimbursement of these two technologies.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaco-economic analysis"

1

Mesquita-Sousa, Dauana, Victoria Miro, Carolina R. Silva, et al. "Use of Terpenoids to Control Helminths in Small Ruminants." In Terpenoids: Recent Advances in Extraction, Biochemistry and Biotechnology. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681089645122010009.

Full text
Abstract:
Gastrointestinal nematodes affect the animal's health and cause economic losses in meat, milk, and wool production. Essential oils and their terpenoids have been shown to effectively control gastrointestinal nematodes and may be an alternative to control gastrointestinal nematodes. The great advantage of terpenoids is the possibility of acting on the parasite in a multidirectional way on the neuromuscular system and body structures of nematodes. The current chapter describes the pharmacological basis of the combination of terpenes and synthetic anthelmintics as an alternative for increasing antiparasitic efficacy. It is necessary to evaluate if these combinations show antagonist, additive or synergic effects at the pharmacokinetic and pharmacodynamic levels. The physicochemical properties, pharmacokinetic features and potential drug drug interactions at the metabolism or transport level of monoterpenes may be relevant for obtaining effective concentrations against different nematodes. In this context, the prediction of absorption, distribution, metabolism and excretion (ADME) is essential to optimize the anthelmintic action of these compounds. The rapid absorption and elimination of monoterpenes after their oral administration may directly influence the drug concentration level attained at the target parasites and the resultant pharmacological effect. Therefore, investigations on the dose schedule, administration route and type of pharmaceutical formulation are necessary. The integration of in vitro assays, in silico analysis, and in vivo pharmaco-parasitological studies are relevant to corroborate the kinetic/metabolic interactions and the efficacy of bioactive natural products combined with synthetic anthelmintics
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaco-economic analysis"

1

Jacobs, VR, M. Braun, N. Harbeck, et al. "Prospective cost analysis from the provider's perspective: pharmaco-economic results from AGO-WSG intergroup adjuvant EC→DOC trial vs. CMF in nodal-positive breast cancer and its reimbursement." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-6111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mansani, Fabio Postiglione, and Morgana Koppen. "Abstract P6-13-06: Pharmaco-economic analysis of the use of the genomic test Mammaprint® for patients with breast cancer treated in a private health institution in Brazil." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p6-13-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sehgal, R., and C. Lark. "Abstract P1-09-03: A Pharmaco-Economic Analysis of Tamoxifen (T) vs. Aromatase Inhibitors (AI) in Adjuvant Treatment of Postmenopausal (PoM) Women (W) with Hormone Receptor Positive (HRP) Breast Cancer (BC)." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p1-09-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaco-economic analysis' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography